Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 5, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 6, 2026
CEOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001638643-26-000010
Filed / recorded
Feb 6, 2026, 9:22 PM UTC
Added to OQRO
Oct 2, 2026, 12:27 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
GILEAD SCIENCES, INC.
Issuer CIK
882095
Ticker
GILD
Reporting person
Daniel Patrick O'day
Relationship
Director, Officer
Officer title
Chairman & CEO
Security
Non-qualified Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Feb 5, 2026
Transaction code
M
Shares / units
115,640
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
0
Ownership form
Direct
Amendment
No
Footnotes from the filing
The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.
The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
